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Nonequimolar-response assays for prostate-specific
antigen (PSA) are criticized for overestimating total
PSA in some men without prostate cancer (PCA), and
underestimating total PSA in some men with PCA. We
recently studied three nonequimolar-response PSA as-
says that had undergone modifications. While two of
the studied assays achieved equimolar-response char-
acteristics with improved areas under receiver operat-
ing characteristic (ROC) curves (AUC), the modifica-
tion of the Chiron ACS PSA assay (ACS PSA2, Chiron)
failed to achieve this. Recently, the ACS assay under-
went another modification (ACS PSA, Bayer), which
we investigated.
Sera from 305 men (155 without and 150 with PCA,
PSA ≥2 and ≤30 µg/l, Tandem-E) were measured using
both modifications of the ACS assay and equimolar-re-
sponse reference methods (Tandem-R free and Tan-
dem-E, Hybritech). Molar response relative to the ref-
erence method and clinical performance (comparison
of AUCs) between the previous and new ACS assay
modifications were studied.
The new modification of the ACS assay (ACS PSA,
Bayer) achieved equimolar-response characteristics
but reported lower values (average 10%) than the Tan-
dem-E assay. Compared to the previous modification
(ACS PSA2, Chiron), a 3% improvement in AUC (p =
0.01) was found. Using results of the redesigned
equimolar-response assay (ACS PSA, Bayer), we calcu-
lated that 6 of 155 men without PCA in this sample set
could be spared unnecessary biopsy compared with
the previous nonequimolar-response assay (ACS
PSA2, Chiron) without missing additional PCA (90%
sensitivity).
These data provide additional evidence for clinical
advantages of equimolar-response over nonequimo-
lar-response PSA assay formats. Clin Chem Lab Med
2003; 41(1):90–94
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Introduction
As initially described by Graves (1) a skewed-response
or nonequimolar-response assay for prostate-specific
antigen (PSA) reports quantities of free PSA as greater
than the same amount of PSA complexed to α1-an-
tichymotrypsin. Therefore, nonequimolar-response as-
says may yield different values for specimens contain-
ing the same amount of total PSA but markedly
different proportions of free PSA (2, 3). The major form
of PSA in serum is that complexed to α1-antichy-
motrypsin (4, 5). This complexed form of PSA is com-
monly present in a higher proportion in men with
prostate cancer (PCA) than in men with benign prostate
conditions, who tend to have higher ratios of free over
total PSA (5). Nonequimolar-response PSA assays
have been criticized for their tendency to overestimate
total PSA in men with benign prostatic hyperplasia,
and underestimate total PSA in men with PCA.
In this context we recently studied three nonequimo-
lar-response PSA assays that were modified by the
manufacturers (Abbott, Wiesbaden, Germany; Bio-
Mérieux, Nürtingen, Germany; Chiron, Fernwald, Ger-
many) (6). We reported on their performance before
and after modification using 338 sera from men with
benign and malignant prostates. All three assays
showed a marked nonequimolar response prior to
modification, among them the ACS PSA2 assay (Chi-
ron). The ACS PSA2 assay (Chiron) represented a pre-
vious modification of the original ACS PSA assay by
Ciba-Corning, which was among the first commercial
PSA assays reported to have a nonequimolar-response
since it detected the free form of PSA with a much
higher sensitivity than the PSA-α1-antichymotrypsin
complex (7–9). After modification the assays by Abbott
and bioMérieux were found to produce an equimolar
response and an improvement in the area under the re-
ceiver operating characteristic (ROC) curve (AUC) was
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observed. The modification of the ACS assay (ACS
PSA2, Chiron) did not demonstrate equimolar-re-
sponse assay characteristics and the AUC remained
unchanged as compared with the original test (6). How-
ever, the modification of the ACS assay (ACS PSA2, Ch-
iron) reported lower total PSA concentrations on test-
ing identical samples (10).
More recently, the ACS PSA2 assay (Chiron) under-
went another new modification and was renamed ACS
PSA (Bayer, Fernwald, Germany), now distributed by
Bayer Diagnostics. With this modification, the poly-
clonal-monoclonal antibodies (ACS PSA2, Chiron)
were replaced by two monoclonal antibodies (ACS
PSA, Bayer), which were adopted from the Bayer Im-
muno I assay. Here we report the changes in molar re-
sponse characteristics and the diagnostic performance
achieved by this new modification.
Materials and Methods
Of the 338 archival sera on which the preceding report (6) was
based, serum aliquots from 305 men (62 men without clinical
evidence of PCA, 93 patients with histologically benign
prostate and 150 patients with untreated PCA) with a total PSA
concentration of ≥2 and ≤30 µg/l (mean 9.1; median 7.0; SD
6.7 (Hybritech, Tandem-E, Krefeld, Germany)) were still avail-
able from the “Assay Comparison Study for PSA” (11). The
study was performed in accordance with practices and ethical
standards of the Committee on Ethical Issues of the University
of Münster and the Declaration of Helsinki including informed
consent of the participants. Clinical and histological validation
of the sera and sample processing were performed as previ-
ously described (6). 
The 305 aliquots were used to determine PSA concentra-
tions using the new modification of the ACS assay (ACS PSA,
Bayer). Results were compared to the concentrations previ-
ously determined in identical samples (6) using the previous
modification of the ACS assay (ACS PSA2, Chiron). Determi-
nations of free and total PSA from an equimolar-response ref-
erence assay combination (Tandem-R free and Tandem-E,
Hybritech) were taken from the study mentioned above and
used to study molar response characteristics as described
previously (6). Clinical performance was evaluated by com-
parison of areas under ROC curves. (12). The ROC curves were
obtained by plotting sensitivities (Y-axis) vs. 1-sensitivities
(X-axis) using all measured PSA concentrations as cut-offs. In
these ROC curves, an ideal diagnostic test yields an AUC of 1
Figure 1 Equimolarity analysis for the previous (ACS PSA2,
Chiron) (A) and new (ACS PSA, Bayer) (B) modification of the
ACS assay for total PSA. Results are obtained from aliquots of
identical serum samples of 150 patients with untreated PCA
and 155 men with benign prostate hypertrophy. Total PSA
concentrations (y-axis) expressed as percent of the equimo-
lar-response reference method (Hybritech, Tandem-E) are
plotted against free/total PSA ratios (Hybritech Tandem-R
free/Tandem-E). The previous modification (ACS PSA2, Chi-
ron) (A) yields a positive slope, indicating that free PSA is
overreported (linear regression). The new modification (ACS
PSA, Bayer) (B) results in a horizontal regression line running
parallel to the dotted 100% reference line which indicates
equimolar-response characteristics, on average reporting ap-
proximately 10% lower total PSA concentrations than the Tan-
dem-E assay.
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and a useless test an AUC of 0.5. For comparison of two meth-
ods, the hypothesis that the difference between the two AUCs
is zero was statistically tested (MedCalc Version 6.0 software,
www.medcalc.be). A p-value < 0.05 was considered to indi-
cate a significant difference in diagnostic performance.
Results
Total PSA concentrations ranged from ≥2 to ≤30 µg/l by
the Tandem-E assay. The free/total PSA ratio ranged
from 0.02 to 0.49 (Tandem-R free/Tandem-E). The PSA
concentrations (µg/l, Hybritech, Tandem-E) in the 150
patients with PCA (mean 12.1; median 11.1; SD 6.7) and
the 155 men without PCA (mean 6.1; median 3.7; SD
5.3) differed as expected.
As previously reported (6), the previous modification
of the ACS assay (ACS PSA2, Chiron) showed a marked
nonequimolar response as indicated by the skewed re-
gression line in Figure 1A. The new modification of the
ACS assay (ACS PSA, Bayer) was found to have an
equimolar response represented by the horizontal re-
gression line in Figure 1B. On average, the new ACS
modification (ACS PSA, Bayer) yielded approximately
10% lower total PSA concentrations than the Tandem-E
assay.
The new ACS modification (ACS PSA, Bayer) on av-
erage yielded slightly higher total PSA (µg/l) concentra-
tions (mean 8.1, range 1.7–26.3, SD 5.7, median 6.3
(95% CI 5.7 to 7.6)) than the previous modification (ACS
PSA2, Chiron) (mean 7.6, range 1.3–35.8, SD 5.9, me-
dian 6.0 (95% CI 5.1 to 7.0)). The mean difference by
paired Student t-test was significant (p < 0.0001). How-
ever, when the data comparing the ACS assays from
Figures 1A and 1B are divided into four segments (de-
pending on the free/total PSA ratio determined by the
Hybritech reference assays), a striking pattern emerges
(see Table 1). In the first segment (free/total PSA ratio
between 0 and 0.099), the nonequimolar-response ACS
assay (ACS PSA2, Chiron) underestimates total PSA
values by an average of –27%, whereas the equimolar-
response ACS assay (ACS PSA, Bayer) underestimates
total PSA values by an average of only –8% (n = 98,
p < 0.001). Conversely, in the fourth segment (free/total
PSA ratio >0.3), the nonequimolar-response ACS assay
(ACS PSA2, Chiron) overestimates total PSA values by
an average of 14%, whereas the equimolar-response
ACS assay (ACS PSA, Bayer) still underestimates total
PSA values by an average of –9% (n = 14, p < 0.001).
These data support the concern that nonequimolar-re-
sponse assays tend to underestimate total PSA in
some men with PCA (especially those patients with low
free/total PSA ratios in the first segment). These data
also demonstrate how nonequimolar-response assays
tend to overestimate total PSA in some men with be-
nign prostates (i.e., patients with high free/total PSA ra-
tios in the fourth segment).
Upon ROC analysis, the new modification (ACS PSA,
Bayer) produced a small but statistically significant im-
provement of the AUC (Figure 2) in comparison to the
previous modification (ACS PSA2, Chiron). The ob-
served 3% gain in AUC is comparable to the AUC in-
creases that Abbott (2%) and bioMérieux (3%) achieved
when replacing their initially nonequimolar-response
assays by an equimolar-response assay format as in-
vestigated in a slightly larger population (6). At 90%
f/t-PSA Hybritech n Average t-PSA Average t-PSA p
Previous ACS modification New ACS modification (Student t-test)
(ACS PSA2, Chiron) (ACS PSA, Bayer)
[% Hybritech] [% Hybritech]
0.000–0.099 98 73% 92% <0.001
0.100–0.199 137 83% 91% <0.001
0.200–0.299 56 95% 95% 0.848
>0.300 14 114% 91% <0.001
Total 305 83% 92% <0.001
Table 1 Comparison of total PSA (t-PSA) results from the
nonequimolar (ACS PSA2, Chiron) and equimolar (ACS PSA,
Bayer) modifications of the ACS assay in different ranges of
the free/total PSA ratio (f/t-PSA).
Figure 2 ROC curves of the previous (ACS PSA2, Chiron;
dotted line) and new (ACS PSA, Bayer; solid line) modification
of the ACS assay. New modification (ACS PSA, Bayer): AUC =
0.80 (95% CI: 0.75–0.84) Previous modification (ACS PSA2,
Chiron): AUC = 0.77 (95% CI: 0.72–0.82) Difference in AUC =
0.03 (95% CI: 0.01–0.04), p = 0.01 (p-value is given for the
tested hypothesis that the difference between the two AUCs is
zero). The new ACS assay modification (ACS PSA, Bayer) cor-
responding to Figure 1B resulted in equimolar assay charac-
teristics with improved diagnostic performance (p = 0.01).
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sensitivity, the specificity of the new modification (ACS
PSA, Bayer) increased from 45% (37–53, 95% CI) to
48% (40–57), thus excluding six of the 155 men without
PCA from biopsy without missing additional PCA. The
cut-offs to achieve 90% sensitivity were 2.9 and 3.5 µg/l
for the previous (ACS PSA2, Chiron) and new modifica-
tion (ACS PSA, Bayer), respectively.
Discussion
Although, theoretically equimolar-response assays
should allow a better discrimination between benign
prostate hyperplasia and PCA, this was only recently
demonstrated in a clinical setting (6). Responding to
Graves’ (1) and subsequently Sokoloff´s (2) early rec-
ommendations, assay producers have withdrawn PSA
assays from the market that did not exhibit equimolar-
response assay characteristics. As was expected (3,
13), assay suppliers who developed assays for free
PSA, but whose total PSA assays were not equimolar-
response assays, made efforts to modify their total
PSA assays. Consequently, nonequimolar-response
assays have already been superseded or withdrawn
(14) and it can be anticipated that more assay modifica-
tions will appear on the market (10).
A platform for the standardization of PSA assays (1,
2, 15) may be achieved by the production of equimolar-
response PSA assays. However, recently Blijenberg
et al. (16) investigated three equimolar-response as-
says before and after recalibration with two calibration
standards and concluded that, even after recalibration,
they were still not completely interchangeable. Despite
the remaining problems in immunoassay standardiza-
tion comprehensively reviewed by Stenman (17), it
should be easier to standardize equimolar-response
PSA assays or, as Stenman proposes, at least achieve a
“harmonization” as an interim solution. A reduction in
interassay variability may be accomplished (18) when
calibrators made available recently (19) are applied to
equimolar-response assays. Until PSA assay standard-
ization is achieved, establishment of assay-specific ref-
erence ranges is strongly recommended to avoid mis-
interpretation of PSA concentrations (10, 13, 20, 21).
As the present study has shown, the new modifica-
tion of the ACS assay (ACS PSA, Bayer) exhibits
equimolar-response assay characteristics (Figure 1B)
in concert with an improvement of diagnostic perfor-
mance (Figure 2). Although the difference in AUC be-
tween the previous (ACS PSA2, Chiron) and new (ACS
PSA, Bayer) ACS assay modifications is relatively
small, it is statistically significant. These data provide
additional evidence for clinical advantages of equimo-
lar-response over nonequimolar-response PSA assay
formats.
Acknowledgements
The PSA comparison study on which this evaluation is based
was financially supported in equal parts by the producers of all
the participating assays. The technical assistance of Francoise
Flammang, Beate Pepping-Schefers, Sabine Plonka, Karin
Hofmann and Ashley Steele is gratefully acknowledged.
References
1. Graves HC. Issues on standardization of immunoassays
for prostate-specific antigen: a review. Clin Invest Med
1993; 16:415–24.
2. Sokoloff RL, Wolfert RL, Rittenhouse HG. Standardization
of PSA immunoasaays: proposals and practical limita-
tions. J Clin Ligand Assay 1995; 18:86–92.
3. Semjonow A, Oberpenning F, Brandt B, Zechel C, Brandau
W, Hertle L. Impact of free prostate-specific antigen on dis-
cordant measurement results of assays for total prostate-
specific antigen. Urology 1996; 48:10–5.
4. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson
O, Pettersson K, et al. Prostate-specific antigen in serum
occurs predominantly in complex with alpha-1-antichy-
motrypsin. Clin Chem 1991; 37:1618–25.
5. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen
K, Alfthan O. A complex between prostate-specific antigen
and alpha 1-antichymotrypsin is the major form of
prostate-specific antigen in serum of patients with prosta-
tic cancer: assay of the complex improves clinical sensitiv-
ity for cancer. Cancer Res 1991; 51:222–6.
6. Semjonow A, Oberpenning F, Weining C, Schön M, Brandt
B, De Angelis G, et al. Do modifications of nonequimolar
assays for total prostate-specific antigen improve detec-
tion of prostate cancer? Clin Chem 2001; 47:1472–5.
7. Strobel SA, Sokoloff RL, Wolfert RL, Rittenhouse HG. Mul-
tiple forms of prostate-specific antigen in serum measured
differently in equimolar- and skewed-response assays.
Clin Chem 1995; 41:125–6.
8. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL.
Multiple forms of prostate-specific antigen in serum: dif-
ferences in immunorecognition by monoclonal and poly-
clonal assays. Clin Chem 1993; 39:2483–91.
9. Bluestein BI, Tewari PC, Weitz S, Zhou A. Multiple forms of
prostate-specific antigen in serum measured differently in
equimolar- and skewed-response assays. Clin Chem 1995;
41:126–7.
10. Semjonow A, De Angelis G, Oberpenning F, Schmid HP,
Brandt B, Hertle L. The clinical impact of different assays
for prostate specific antigen. BJU Int 2000; 86:590–7.
11. Semjonow A, Weining C, Oberpenning F, Heinecke A,
Terpe A, Schmid HP, et al. Application of assay-specific cut-
off values: results of the assay comparison study for PSA.
Eur Urol 1999; 35 (Suppl 2):18.
12. Hanley JA, McNeil BJ. A method of comparing the areas
under receiver operating characteristic curves derived
from the same cases. Radiology 1983; 148:839–43.
13. Semjonow A, Brandt B, Oberpenning F, Roth S, Hertle L.
Discordance of assay methods creates pitfalls for the inter-
pretation of prostate-specific antigen values. Prostate
1996; 7:3–16.
14. Ward AM, Catto JW, Hamdy FC. Prostate specific antigen:
biology, biochemistry and available commercial assays.
Ann Clin Biochem 2001; 38:633–51.
15. Graves HC. Standardization of immunoassays for
prostate-specific antigen. A problem of prostate-specific
antigen complexation or a problem of assay design? Can-
cer 1993; 72:3141–4.
16. Blijenberg BG, Storm BN, Kruger AE, Schröder FH. On the
standardization of total prostate-specific antigen: an exer-
cise with two reference preparations. Clin Chem Lab Med
1999; 37:545–52.
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 12:19
94 Oberpenning et al.: A new modification of the ACS assay for total PSA
17. Stenman UH. Immunoassay standardization: is it possible,
who is responsible, who is capable? Clin Chem 2001;
47:815–20.
18. Chan DW, Sokoll LJ. WHO first international standards for
prostate-specific antigen: the beginning of the end for as-
say discrepancies? Clin Chem 2000; 46:1291–2.
19. Rafferty B, Rigsby P, Rose M, Stamey T, Gaines Das R. Ref-
erence reagents for prostate-specific antigen (PSA): estab-
lishment of the first international standards for free PSA
and PSA (90:10). Clin Chem 2000; 46:1310–7.
20. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH,
Wildhagen MF, Schröder FH. Discordant performance of
assays for free and total prostate-specific antigen in rela-
tion to the early detection of prostate cancer. BJU Int 2001;
88:545–50.
21. Jung K, Lein M, Schnorr D, Brux B, Henke W, Loening S.
Comparison between equimolar- and skewed-response
assays of prostate specific antigen: is there an influence on
the clinical significance when measuring total serum
prostate specific antigen? Ann Clin Biochem 1996;
33:209–14.
Received 11 June 2002, revised 12 September 2002, 
accepted 4 October 2003
Corresponding author: Frank Oberpenning, M.D., 
University of Münster, Department of Urology,
Albert-Schweitzer-Str. 33, 48129 Münster, Germany
Phone: +49 251-834 7443, Fax: +49 251-834 8492
E-mail: oberpen@uni-muenster.de
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 12:19
